Literature DB >> 11872423

Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.

Lucie Heinzerling1, Reinhard Dummer, Günter Burg, Peter Schmid-Grendelmeier.   

Abstract

BACKGROUND: Interferons are used in the immune therapy of multiple sclerosis, Kaposi's sarcoma, hepatitis and melanoma based on their antiviral, immunoregulatory and antitumor activities. We report a rare side effect observed during treatment of multiple sclerosis with subcutaneous interferon beta injections. OBSERVATIONS: A 44-year-old patient diagnosed with multiple sclerosis received immune therapy with 6 Mio IU recombinant interferon-beta (IFN-beta) every other day. After 4 years of subcutaneous interferon injections painful indurations appeared directly at and adjacent to the injection sites on the thighs, arms and abdomen. Pain in the thighs made walking almost impossible and required therapy with opiates. After changing to another interferon-beta medication the symptoms improved. Subsequent treatment with doxycycline for 3 weeks was of no additional benefit.
CONCLUSIONS: Panniculitis at the injection sites is a rare event but has a significant impact on the quality of life during interferon therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872423

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  2 in total

1.  Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.

Authors:  S S O'Sullivan; E M Cronin; B J Sweeney; J F Bourke; J Fitzgibbon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-16       Impact factor: 10.154

2.  Case Report: Generalised Panniculitis as a Post-COVID-19 Presentation in Aicardi-Goutières Syndrome Treated With Ruxolitinib.

Authors:  Abirami Pararajasingam; Rachel E Bradley; Jennifer Evans; Ashima Lowe; Richard Goodwin; Stephen Jolles
Journal:  Front Pediatr       Date:  2022-04-25       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.